Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nanvuranlat - J-Pharma

Next Previous
Drug Profile

Nanvuranlat - J-Pharma

Alternative Names: JPH-203; JPH-203SBECD; KYT-0353

Latest Information Update: 06 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator J-Pharma
  • Class Amines; Antifibrotics; Antineoplastics; Benzoxazoles; Chlorobenzenes; Phenyl ethers; Small molecules
  • Mechanism of Action Amino acid transport system L inhibitors; Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Biliary cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Biliary cancer
  • Phase II Colorectal cancer
  • Preclinical Idiopathic pulmonary fibrosis

Most Recent Events

  • 01 Jan 2026 Phase-III clinical trials in Biliary cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (IV-infusion) (NCT07265674)
  • 05 Dec 2025 J-Pharma plans a phase III trial for Biliary cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (IV, Infusion) (NCT07265674)
  • 05 Dec 2025 Nanvuranlat is still in preclinical trials for Biliary cancer in USA (NCT07265674)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top